Oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
An	an	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
some	some	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
all	all	O	O	O	O
,	,	O	O	O	O
studies	studies	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
investigated	investigated	O	O	O	O
this	this	O	O	O	O
association	association	O	O	O	O
,	,	O	O	O	O
according	according	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
type	type	O	O	O	O
of	of	O	O	O	O
progestagen	progestagen	O	O	OTHERS	I
included	included	O	O	O	O
in	in	O	O	O	O
third-generation	third-generation	O	O	O	O
(	(	O	O	O	O
i.e.	i.e.	O	O	O	O
,	,	O	O	O	O
desogestrel	desogestrel	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
gestodene	gestodene	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
second-generation	second-generation	O	O	O	O
(	(	O	O	O	O
i.e.	i.e.	O	O	O	O
,	,	O	O	O	O
levonorgestrel	levonorgestrel	O	O	OTHERS	I
)	)	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
estrogen	estrogen	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
presence	presence	O	O	O	O
or	or	O	O	O	O
absence	absence	O	O	O	O
of	of	O	O	O	O
prothrombotic	prothrombotic	O	O	O	O
mutations	mutations	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
a	a	O	O	O	O
nationwide	nationwide	O	O	O	O
,	,	O	O	O	O
population-based	population-based	O	O	O	O
,	,	O	O	O	O
case-control	case-control	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
identified	identified	O	O	O	O
and	and	O	O	O	O
enrolled	enrolled	O	O	O	O
248	248	O	O	O	O
women	women	O	O	O	O
18	18	O	O	O	O
through	through	O	O	O	O
49	49	O	O	O	O
years	years	O	O	O	O
of	of	O	O	O	O
age	age	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
first	first	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
between	between	O	O	O	O
1990	1990	O	O	O	O
and	and	O	O	O	O
1995	1995	O	O	O	O
and	and	O	O	O	O
925	925	O	O	O	O
control	control	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
not	not	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
and	and	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
matched	matched	O	O	O	O
for	for	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
calendar	calendar	O	O	O	O
year	year	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
index	index	O	O	O	O
event	event	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
area	area	O	O	O	O
of	of	O	O	O	O
residence	residence	O	O	O	O
.	.	O	O	O	O

Subjects	subjects	O	O	O	O
supplied	supplied	O	O	O	O
information	information	O	O	O	O
on	on	O	O	O	O
oral-contraceptive	oral-contraceptive	O	O	O	O
use	use	O	O	O	O
and	and	O	O	O	O
major	major	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
.	.	O	O	O	O

An	an	O	O	O	O
analysis	analysis	O	O	O	O
for	for	O	O	O	O
factor	factor	CHEMICALS	O	OTHERS	I
V	v	CHEMICALS	O	OTHERS	I
Leiden	leiden	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
G20210A	g20210a	O	O	O	O
mutation	mutation	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prothrombin	prothrombin	O	O	O	O
gene	gene	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
in	in	O	O	O	O
217	217	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
763	763	O	O	O	O
controls	controls	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
odds	odds	O	O	O	O
ratio	ratio	O	O	O	O
for	for	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
among	among	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
any	any	O	O	O	O
type	type	O	O	O	O
of	of	O	O	O	O
combined	combined	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptive	contraceptive	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
as	as	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
nonusers	nonusers	O	O	O	O
,	,	O	O	O	O
was	was	O	O	O	O
2.0	2.0	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
percent	percent	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
1.5	1.5	O	O	O	O
to	to	O	O	O	O
2.8	2.8	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
adjusted	adjusted	O	O	O	O
odds	odds	O	O	O	O
ratio	ratio	O	O	O	O
was	was	O	O	O	O
2.5	2.5	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
percent	percent	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
1.5	1.5	O	O	O	O
to	to	O	O	O	O
4.1	4.1	O	O	O	O
)	)	O	O	O	O
among	among	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
second-generation	second-generation	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
1.3	1.3	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
percent	percent	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
0.7	0.7	O	O	O	O
to	to	O	O	O	O
2.5	2.5	O	O	O	O
)	)	O	O	O	O
among	among	O	O	O	O
those	those	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
third-generation	third-generation	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Among	among	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
odds	odds	O	O	O	O
ratio	ratio	O	O	O	O
was	was	O	O	O	O
2.1	2.1	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
percent	percent	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
1.5	1.5	O	O	O	O
to	to	O	O	O	O
3.0	3.0	O	O	O	O
)	)	O	O	O	O
for	for	O	O	O	O
those	those	O	O	O	O
without	without	O	O	O	O
a	a	O	O	O	O
prothrombotic	prothrombotic	O	O	O	O
mutation	mutation	O	O	O	O
and	and	O	O	O	O
1.9	1.9	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
percent	percent	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
0.6	0.6	O	O	O	O
to	to	O	O	O	O
5.5	5.5	O	O	O	O
)	)	O	O	O	O
for	for	O	O	O	O
those	those	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
mutation	mutation	O	O	O	O
CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
was	was	O	O	O	O
increased	increased	O	O	O	O
among	among	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
second-generation	second-generation	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
with	with	O	O	O	O
respect	respect	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
third-generation	third-generation	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
inconclusive	inconclusive	O	O	O	O
but	but	O	O	O	O
suggested	suggested	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
was	was	O	O	O	O
lower	lower	O	O	O	O
than	than	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
second-generation	second-generation	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
infarction	infarction	O	DISEASE	OTHERS	I
was	was	O	O	O	O
similar	similar	O	O	O	O
among	among	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
oral	oral	CHEMICALS	O	OTHERS	I
contraceptives	contraceptives	CHEMICALS	O	OTHERS	I
whether	whether	O	O	O	O
or	or	O	O	O	O
not	not	O	O	O	O
they	they	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
prothrombotic	prothrombotic	O	O	O	O
mutation	mutation	O	O	O	O
.	.	O	O	O	O

